LRRK2 is expressed in B-2 but not in B-1 B cells, and downregulated by cellular activation

Journal of Neuroimmunology

Volumn 229, Issue 1-2, 2010, Pages 123-128

  Kubo, Makoto ^a   Kamiya, Yoshiko ^a   Nagashima, Ryuichi ^a   Maekawa, Tatsunori ^a   Eshima, Koji ^b   Azuma, Sadahiro ^b   Ohta, Etsuro ^a   Obata, Fumiya ^a  

^a KITASATO UNIVERSITY   (Japan)

^b KITASATO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

B 1 cells; B 2 cells; Downregulation; Leucine rich repeat kinase 2; PARK8; Parkinson's disease

Indexed keywords

LEUCINE RICH REPEAT KINASE 2;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; B 1 LYMPHOCYTE; B 2 LYMPHOCYTE; B LYMPHOCYTE; B LYMPHOCYTE ACTIVATION; BLOOD CELL; BONE MARROW CELL; CELL MATURATION; CELL STRAIN; CELL STRAIN B 1; CELL STRAIN B 2; CONTROLLED STUDY; DOWN REGULATION; FEMALE; LYMPHOCYTE FUNCTION; MOUSE; NONHUMAN; PERITONEAL CAVITY; PRE B LYMPHOCYTE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; SPLEEN CELL; T LYMPHOCYTE;

ANIMALS; B-LYMPHOCYTE SUBSETS; DOWN-REGULATION; FEMALE; FLOW CYTOMETRY; IONOMYCIN; IONOPHORES; LIPOPOLYSACCHARIDES; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; PROTEIN-SERINE-THREONINE KINASES; RNA, MESSENGER; TETRADECANOYLPHORBOL ACETATE;

EID: 78649342837     PISSN: 01655728     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jneuroim.2010.07.021     Document Type: Article

References (43)

1. Baba Y., Kuroiwa A., Uitti R.J., Wszolek Z.K., Yamada T. Alterations of T-lymphocyte populations in Parkinson disease. Parkinsonism Relat. Disord. 2005, 11:493-498.
2. Baumgarth N., Herman O.C., Jager G.C., Brown L., Herzenberg L.A. Innate and acquired humoral immunities to influenza virus are mediated by distinct arms of the immune system. Proc. Natl. Acad. Sci. U.S.A. 1999, 96:2250-2255.
3. Berland R., Wortis H.H. Origins and functions of B-1 cells with notes on the role of CD5. Annu. Rev. Immunol. 2002, 20:253-300.
4. Biskup S., Moore D.J., Rea A., Lorenz-Deperieux B., Coombes C.E., Dawson V.L., Dawson T.M., West A.B. Dynamic and redundant regulation of LRRK2 and LRRK1 expression. BMC Neurosci. 2007, 8:102.
5. Brochard V., Combadiere B., Prigent A., Laouar Y., Perrin A., Beray-Berthat V., Bonduelle O., Alvarez-Fischer D., Callebert J., Launay J.M., Duyckaerts C., Flavell R.A., Hirsch E.C., Hunot S. Infiltration of CD4+ lymphocytes into the brain contributes to neurodegeneration in a mouse model of Parkinson disease. J. Clin. Invest. 2009, 119:182-192.
6. Dasu T., Sindhava V., Clarke S.H., Bondada S. CD19 signaling is impaired in murine peritoneal and splenic B-1 B lymphocytes. Mol. Immunol. 2009, 46:2655-2665.
7. Deng J., Lewis P.A., Greggio E., Sluch E., Beilina A., Cookson M.R. Structure of the ROC domain from the Parkinson's disease-associated leucine-rich repeat kinase 2 reveals a dimeric GTPase. Proc. Natl. Acad. Sci. U.S.A. 2008, 105:1499-1504.
8. Double K.L., Rowe D.B., Carew-Jones F.M., Hayes M., Chan D.K., Blackie J., Corbett A., Joffe R., Fung V.S., Morris J., Riederer P., Gerlach M., Halliday G.M. Anti-melanin antibodies are increased in sera in Parkinson's disease. Exp. Neurol. 2009, 217:297-301.
9. Durand C.A., Hartvigsen K., Fogelstrand L., Kim S., Iritani S., Vanhaesebroeck B., Witztum J.L., Puri K.D., Gold M.R. Phosphoinositide 3-kinase p110 delta regulates natural antibody production, marginal zone and B-1 B cell function, and autoantibody responses. J. Immunol. 2009, 183:5673-5684.
10. Fagarasan S., Shinkura R., Kamata T., Nogaki F., Ikuta K., Tashiro K., Honjo T. Alymphoplasia (aly)-type nuclear factor kappaB-inducing kinase (NIK) causes defects in secondary lymphoid tissue chemokine receptor signaling and homing of peritoneal cells to the gut-associated lymphatic tissue system. J. Exp. Med. 2000, 191:1477-1486.
11. Funayama M., Hasegawa K., Kowa H., Saito M., Tsuji S., Obata F. A new locus for Parkinson's disease (PARK8) maps to chromosome 12p11.2-q13.1. Ann. Neurol. 2002, 51:296-301.
12. Funayama M., Hasegawa K., Ohta E., Kawashima N., Komiyama M., Kowa H., Tsuji S., Obata F. An LRRK2 mutation as a cause for the parkinsonism in the original PARK8 family. Ann. Neurol. 2005, 57:918-921.
13. Gandhi P.N., Wang X., Zhu X., Chen S.G., Wilson-Delfosse A.L. The Roc domain of leucine-rich repeat kinase 2 is sufficient for interaction with microtubules. J. Neurosci. Res. 2008, 86:1711-1720.
14. Gulley M.L., Ogata L.C., Thorson J.A., Dailey M.O., Kemp J.D. Identification of a murine pan-T cell antigen which is also expressed during the terminal phases of B cell differentiation. J. Immunol. 1988, 140:3751-3757.
15. Hardy R.R. B-1 B cells: development, selection, natural autoantibody and leukemia. Curr. Opin. Immunol. 2006, 18:547-555.
16. Hardy R.R., Hayakawa K. B cell development pathways. Annu. Rev. Immunol. 2001, 19:595-621.
17. Hayakawa K., Hardy R.R., Parks D.R., Herzenberg L.A. The "Ly-1 B" cell subpopulation in normal immunodefective, and autoimmune mice. J. Exp. Med. 1983, 157:202-218.
18. Hayakawa K., Hardy R.R., Honda M., Herzenberg L.A., Steinberg A.D. Ly-1 B cells: functionally distinct lymphocytes that secrete IgM autoantibodies. Proc. Natl. Acad. Sci. U.S.A. 1984, 81:2494-2498.
19. Hein K., Lorenz M.G., Siebenkotten G., Petry K., Christine R., Radbruch A. Processing of switch transcripts is required for targeting of antibody class switch recombination. J. Exp. Med. 1998, 188:2369-2374.
20. Herzenberg L.A. B-1 cells: the lineage question revisited. Immunol. Rev. 2000, 175:9-22.
21. Higashi S., Biskup S., West A.B., Trinkaus D., Dawson V.L., Faull R.L., Waldvogel H.J., Arai H., Dawson T.M., Moore D.J., Emson P.C. Localization of Parkinson's disease-associated LRRK2 in normal and pathological human brain. Brain Res. 2007, 1155:208-219.
22. Higashi S., Moore D.J., Colebrooke R.E., Biskup S., Dawson V.L., Arai H., Dawson T.M., Emson P.C. Expression and localization of Parkinson's disease-associated leucine-rich repeat kinase 2 in the mouse brain. J. Neurochem. 2007, 100:368-381.
23. Holodick N.E., Tumang J.R., Rothstein T.L. Continual signaling is responsible for constitutive ERK phosphorylation in B-1a cells. Mol. Immunol. 2009, 46:3029-3036.
24. Hsu C.H., Chan D., Greggio E., Saha S., Guillily M.D., Ferree A., Raghavan K., Shen G.C., Segal L., Ryu H., Cookson M.R., Wolozin B. MKK6 binds and regulates expression of Parkinson's disease-related protein LRRK2. J. Neurochem. 2010, 112:1593-1604.
25. Imai Y., Gehrke S., Wang H.Q., Takahashi R., Hasegawa K., Oota E., Lu B. Phosphorylation of 4E-BP by LRRK2 affects the maintenance of dopaminergic neurons in Drosophila. EMBO J. 2008, 27:2432-2443.
26. Ito G., Okai T., Fujino G., Takeda K., Ichijo H., Katada T., Iwatsubo T. GTP binding is essential to the protein kinase activity of LRRK2, a causative gene product for familial Parkinson's disease. Biochemistry 2007, 46:1380-1388.
27. Jaleel M., Nichols R.J., Deak M., Campbell D.G., Gillardon F., Knebel A., Alessi D.R. LRRK2 phosphorylates moesin at threonine-558: characterization of how Parkinson's disease mutants affect kinase activity. Biochem. J. 2007, 405:307-317.
28. Larsen K., Madsen L.B. Sequence conservation between porcine and human LRRK2. Mol. Biol. Rep. 2009, 36:237-243.
29. Maekawa T., Kubo M., Yokoyama I., Ohta E., Obata F. Age-dependent and cell-population-restricted LRRK2 expression in normal mouse spleen. Biochem. Biophys. Res. Commun. 2010, 392:431-435.
30. Melrose H., Lincoln S., Tyndall G., Dickson D., Farrer M. Anatomical localization of leucine-rich repeat kinase 2 in mouse brain. Neuroscience 2006, 139:791-794.
31. Meylan E., Tschopp J. The RIP kinases: crucial integrators of cellular stress. Trends Biochem. Sci. 2005, 30:151-159.
32. Miyawaki S., Nakamura Y., Suzuka H., Koba M., Yasumizu R., Ikehara S., Shibata Y. A new mutation, aly, that induces a generalized lack of lymph nodes accompanied by immunodeficiency in mice. Eur. J. Immunol. 1994, 24:429-434.
33. Orr C.F., Rowe D.B., Mizuno Y., Mori H., Halliday G.M. A possible role for humoral immunity in the pathogenesis of Parkinson's disease. Brain 2005, 128:2665-2674.
34. Paisan-Ruiz C., Jain S., Evans E.W., Gilks W.P., Simon J., van der Brug M., Lopez de Munain A., Aparicio S., Gil A.M., Khan N., Johnson J., Martinez J.R., Nicholl D., Carrera I.M., Pena A.S., de Silva R., Lees A., Marti-Masso J.F., Perez-Tur J., Wood N.W., Singleton A.B. Cloning of the gene containing mutations that cause PARK8-linked Parkinson's disease. Neuron 2004, 44:595-600.
35. Rosenstein Y., Santana A., Pedraza-Alva G. CD43, a molecule with multiple functions. Immunol. Res. 1999, 20:89-99.
36. Shinkura R., Kitada K., Matsuda F., Tashiro K., Ikuta K., Suzuki M., Kogishi K., Serikawa T., Honjo T. Alymphoplasia is caused by a point mutation in the mouse gene encoding Nf-kappa b-inducing kinase. Nat. Genet. 1999, 22:74-77.
37. Simon-Sanchez J., Herranz-Perez V., Olucha-Bordonau F., Perez-Tur J. LRRK2 is expressed in areas affected by Parkinson's disease in the adult mouse brain. Eur. J. Neurosci. 2006, 23:659-666.
38. Smith W.W., Pei Z., Jiang H., Dawson V.L., Dawson T.M., Ross C.A. Kinase activity of mutant LRRK2 mediates neuronal toxicity. Nat. Neurosci. 2006, 9:1231-1233.
39. Tan E.K., Sie L., Loong S. Growth rate of patient-derived lymphoblastoid cells with LRRK2 mutations. Mol. Genet. Metab. 2008, 95:113.
40. Wells S.M., Kantor A.B., Stall A.M. CD43 (S7) expression identifies peripheral B cell subsets. J. Immunol. 1994, 153:5503-5515.
41. West A.B., Moore D.J., Choi C., Andrabi S.A., Li X., Dikeman D., Biskup S., Zhang Z., Lim K.L., Dawson V.L., Dawson T.M. Parkinson's disease-associated mutations in LRRK2 link enhanced GTP-binding and kinase activities to neuronal toxicity. Hum. Mol. Genet. 2007, 16:223-232.
42. Westerlund M., Belin A.C., Anvret A., Bickford P., Olson L., Galter D. Developmental regulation of leucine-rich repeat kinase 1 and 2 expression in the brain and other rodent and human organs: implications for Parkinson's disease. Neuroscience 2008, 152:429-436.
43. Zimprich A., Biskup S., Leitner P., Lichtner P., Farrer M., Lincoln S., Kachergus J., Hulihan M., Uitti R.J., Calne D.B., Stoessl A.J., Pfeiffer R.F., Patenge N., Carbajal I.C., Vieregge P., Asmus F., Muller-Myhsok B., Dickson D.W., Meitinger T., Strom T.M., Wszolek Z.K., Gasser T. Mutations in LRRK2 cause autosomal-dominant parkinsonism with pleomorphic pathology. Neuron 2004, 44:601-607.